Profusa shares traded at $0.90 on August 15, with volume of 46,269 shares against a 223,125-share average. The stock's 52-week range spans $0.81 to $1,297.50, reflecting the extreme compression since the company began trading on Nasdaq after its July 2025 SPAC merger with NorthView Acquisition. Market capitalization stood at roughly $170,000. Technical analysis noted the stock slipping 4.42% to $0.92 on August 13, testing support at $0.87 with resistance at $0.97.
The reverse split is widely viewed as a compliance measure to maintain Nasdaq listing standards given the sub-$1 trading price. Post-split, the nominal share price would theoretically quadruple while market capitalization remains unchanged, though liquidity and volatility dynamics often shift. Weiss Ratings maintains a "sell (e+)" rating on PFSA.
HRT Financial LP's broader August activity across other micro-cap names — including sales in Maison Solutions and Kidz AI — suggests active portfolio management rather than a Profusa-specific signal. The firm filed Form 3 initial ownership reports for Airwa Inc. (YYAI) and Lion Group Holding (LGHL) in late July and early August, listing its address as 3 World Trade Center, 76th Floor, New York.
The discrepancy between the Investing.com headline citing a $1,234 sale and the SEC-derived figure of $37,745.79 underscores the need to verify insider transaction data against primary filings. With the reverse split imminent, the key question becomes whether HRT Financial LP's reduced position reflects a tactical exit ahead of a technical reset or a broader reallocation away from micro-cap biosensor equities.